news
Daiichi Sankyo’s edoxaban launched in the UK
10 July 2015 | By Victoria White
Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK...
List view / Grid view
Venous thromboembolism (VTE)
news
NICE guidance recommends anti-blood clotting drug apixaban
9 June 2015 | By NICE
NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults...
news
New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer
29 May 2015 | By VIctoria White
Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer...
news
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
news
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
news
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
news
Portola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the Phase 3 ANNEXA™-A studies of investigational Andexanet Alfa with Eliquis (apixaban)
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...
news
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
news
Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
news
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
22 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation...
news
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
news
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
news
FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
news
Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies...
news
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
